Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Stock Information for Compugen Ltd.
Loading
Please wait while we load your information from QuoteMedia.